MARKET

XFOR

XFOR

X4 Pharmaceuticals Inc
NASDAQ
4.150
+0.390
+10.37%
After Hours: 4.120 -0.03 -0.72% 19:01 03/09 EDT
OPEN
3.750
PREV CLOSE
3.760
HIGH
4.160
LOW
3.700
VOLUME
590.52K
TURNOVER
--
52 WEEK HIGH
10.67
52 WEEK LOW
1.350
MARKET CAP
362.86M
P/E (TTM)
-0.3951
1D
5D
1M
3M
1Y
5Y
1D
X4 Pharmaceuticals Price Target Announced at $12.00/Share by Guggenheim
Dow Jones · 13h ago
Guggenheim Initiates Coverage On X4 Pharmaceuticals with Buy Rating, Announces Price Target of $12
Benzinga · 13h ago
X4 Pharmaceuticals initiated with a Buy at Guggenheim
TipRanks · 16h ago
Weekly Report: what happened at XFOR last week (0302-0306)?
Weekly Report · 17h ago
X4 Pharmaceuticals to Join Fireside Chat at Leerink Global Healthcare Conference
Reuters · 5d ago
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval
Seeking Alpha · 6d ago
X4 Pharmaceuticals Grants 24,000-Share Inducement Stock Options to New Hires
Reuters · 03/02 21:30
X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 03/02 21:30
More
About XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Webull offers X4 Pharmaceuticals Inc stock information, including NASDAQ: XFOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XFOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XFOR stock methods without spending real money on the virtual paper trading platform.